Observational studyFrontiers in immunology2026
The impact of shared decision-making on quality of life in systemic lupus erythematosus practice: findings from the TRUMP
Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Shared decision-making (SDM) is increasingly emphasized in the treatment of systemic lupus erythematosus (SLE). Although SDM has been linked to quality of life (QoL) in various diseases, its direct and quantitative relationship with QoL in SLE remains unclear. This study aimed to investigate the longitudinal relationship between SDM and QoL in a multicenter cohort of patients with SLE. Methods: Patients aged 20 years or older diagnosed with SLE according to the 1997 revised American College of Rheumatology criteria were included. The association between baseline scores on the SDM-Q-9, an indicator of SDM, and one-year changes in scores on the LupusPRO, a QoL measure for patients with SLE, was examined using multiple regression analysis. Additionally, we evaluated the association between SDM changes and QoL, both overall and across the four groups, categorized by baseline SDM levels and SDM changes. Results: A total of 436 patients were included in this analysis. Higher baseline SDM-Q-9 scores were associated with a 0.16-point improvement (95% confidence interval [CI]: 0.071-0.24, Conclusions: Higher SDM levels in patients with SLE may enhance their QoL. Sustained high SDM appears to be more influential than short-term improvements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.